New shot for bulging eyes moves to final testing phase

NCT ID NCT07155668

First seen Nov 01, 2025 · Last updated May 12, 2026 · Updated 21 times

Summary

This study tests an investigational drug called VRDN-003 for people with thyroid eye disease (TED). The main goal is to see if the drug is safe and how the body processes it. About 87 adults with TED will receive the drug as a shot under the skin. This is a Phase 3 trial, meaning the drug is in the final stage of testing before possible approval.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for THYROID EYE DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Advanced Quality Medical Research, LLC

    Orland Park, Illinois, 60462, United States

  • Baylor College of Medicine, Alkek Eye Center

    Houston, Texas, 77030, United States

  • C&A Clinical Trials Corp

    Cape Coral, Florida, 33990, United States

  • Continental Clinical Research, llc

    Miami, Florida, 33144, United States

  • Fraser Eye Center

    Fraser, Michigan, 48026, United States

  • Hype Clinical Research, LLC

    Miami, Florida, 33145, United States

  • Ilumina Medical Research

    Kissimmee, Florida, 34744, United States

  • Kahana Oculoplastic and Orbital Surgery

    Livonia, Michigan, 48152, United States

  • Med-Care Research

    Miami, Florida, 33125, United States

  • Neuro Eye Clinical Trials INC

    Houston, Texas, 77074, United States

  • Ophthalmic Consultants of Boston

    East Weymouth, Massachusetts, 02189, United States

  • United Medical Research Institute

    Inglewood, California, 90301, United States

  • Vector Clinical Trials

    Sparks, Nevada, 89128, United States

Conditions

Explore the condition pages connected to this study.